Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was originally established in 1999 as a spin-off from Lund University. The business is located in Sweden, where research is conducted in-house but also through international partners. The company is headquartered in Lund.

Quotes for Respiratorius AB

Right Now

+/-
-0.13
%
−4,85%
Latest
2.55
High
2.76
Low
2.55
Volume
39 440
Turnover (SEK)
106 115
Market Value (MSEK)
20,2
Time (Latest trade)

Board

CEO

  • Johan Drott

Chairperson of the Board

  • Karin Wehlin

Board

  • Johan Drott
  • Kristina Drott
  • Mia Lundblad
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Bolagspresentation och Q&A med Johan Drott

    Johan Drott CEO presenterar på Life Science Day 2019

    Johan Drott CEO, presenterar på Redeye Investor Forum - 10 sep

    Johan Drott, CEO Respiratorius

    Largest Owners

    Name Capital % Votes % Date
    Avanza Pension 5,87 5,87 2025-09-26
    Valcuria Holding AB 3,70 3,70 2025-09-26
    Hartmut Wiese 2,53 2,53 2025-09-26
    Hans Mandahl 1,65 1,65 2025-09-26
    Ulf Stahlin 1,21 1,21 2025-09-26
    Håkan Svensson 1,14 1,14 2025-09-26
    Gerhard Dal 1,11 1,11 2025-09-26
    Per Vasilis 1,11 1,11 2025-09-26
    Patrik Steve-Erik Jonsson 1,03 1,03 2025-09-26
    Erik Boström 1,00 1,00 2025-09-26
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2025-11-11 Delårsrapport 2025-Q3

    • 2026-02-10 Bokslutskommuniké 2025

    Annual reports, prospectus etc.